Divi’s Laboratories announced a robust financial performance for the March quarter of FY25, with a 25.6% YoY surge in standalone net profit, reaching Rs 667 crore. Revenue from operations also climbed by 12.26% to Rs 2,536 crore. The company’s board declared a dividend of Rs 30 per share and its Unit III greenfield project has commenced commercial operations.
Sebi board meeting: PMS rules overhaul, FPI commodity trades among key decisions to watch out
Sebi’s upcoming board meeting aims to discuss significant changes to portfolio management services and settlement regulations. Proposed revisions could allow discretionary portfolio managers to make